Formulation, evaluation and optimization of bilayer tablet of risedronate sodium and diclofenac sodium for corticosteroid induced osteoporosis
Kuldeep H Ramteke and Mayadevi U Tate
PES’s Modern College of Pharmacy, India
: J Pharm Drug Deliv Res
Abstract
The aim of present invention is to Formulation and Evaluation of Bilayer Tablet of Risedronate Sodium and Diclofenac Sodium. Risedronate Sodium is used for the treatment of corticosteroid induced osteoporosis in men and women and postmenopausal osteoporosis in women. Bi-layer tablet is a new approach for successful development of controlled release formulation along with various features to provide successful drug delivery. Two layers (immediate release layer and controlled release layer) were formulated separately using different polymer and compressed by using direct compression technique. In dissolution study first drug i.e. Risedronate Sodium releases within 30 min. which is desired criteria then the second drug i.e. Diclofenac Sodium showed sustained release up to 12 hours. According to results of percentage cumulative drug release, it was concluded that F9 and F5 were optimized batches for IR and SR respectively. Release kinetics was carried out and it was found to be zero order release and from assay drug content was found to be in limits. The formulation was compared with marketed formulations and found f1 and f2 factor which showed good results.
Biography
